LINKING THEORY TO PRACTICE: UNDERUSE OF CHRONIC ORAL ANTICOAGULATION IN ATRIAL FIBRILLATION

  • Alexandra STOICA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Victorita SORODOC “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Catalina LIONTE “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Oana SIRBU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • O.R. PETRIS “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • A. CEASOVSCHIH “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • L. SORODOC “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

The effectiveness of chronic oral anticoagulation in preventing thromboembolic events related to atrial fibrillation has already been proven. Nevertheless, a suboptimal use of oral anticoagulants is documented in real-world practice. Aim: To characterize individuals diagnosed with atrial fibrillation in need of chronic oral anticoagulation for thromboembolic prophylactic purposes, focusing on primary reasons of inadequate anticoagulation (lack of recommendation from the attending physician, inappropriate dosing and/or presence of contraindications). Material and methods: Patients presenting atrial fibrillation on admission or having been previously diagnosed with at least one episode of atrial fibrillation were included. Parameters like the type of atrial fibrillation (newly diagnosed, paroxysmal, persistent, permanent), associated thromboembolic and bleeding risk factors, as well as the long-term use of oral anticoagulants were assessed. Results: The study group comprised 90 subjects (mean age 75.83 ± 8.75 years, 40% men). All patients associated high thromboembolic risk according to CHA2DS2-VASC score. In one third of the patients no objective reason justifying the lack of anticoagulation was found. A reduced glomerular filtration rate (<60 mL/min/1.73 m2) was noted in 34.4% of the study group. Conclusions: Our study confirmed the underuse of oral anticoagulants in patients with atrial fibrillation. If pathological conditions predisposing to high bleeding risk were excluded, the socioeconomic status represented the main argument when establishing the need for oral anticoagulation. Additional strategies to promote public awareness are needed in patients with atrial fibrillation requiring antithrombotic treatment.

Author Biographies

Alexandra STOICA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

Victorita SORODOC, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

Catalina LIONTE, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

Oana SIRBU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

O.R. PETRIS, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

A. CEASOVSCHIH, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

L. SORODOC, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Faculty of Medicine
Department of Medical Specialties (III)

References

1. Christiansen CB, Gerds TA, Olesen JB, Kristensen SL, Lamberts M, Lip GYH et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace 2016; 18: 1689-1697.
2. Ansari JG, Garcha GS, Lakkis N. Oral anticoagulation in atrial fibrillation. Cardiovasc Hematol Agents Med Chem 2014; 12: 34-41.
3. Hagerty T, Rich MW. Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleve Clin J Med 2017; 84(1): 35-40.
4. Gross AF, Stern TA. The Cognitive Impact of Atrial Fibrillation. Prim Care Companion CNS Disord 2013; 15(1): PCC.12f01471.
5. Garkina SV, Vavilova TV, Lebedev DS, Mikhaylov EN. Compliance and adherence to oral anticoag-ulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol 2016; 13(9): 807-810.
6. Johansson C, Hägg L, Johansson L, Jansson JH. Characterization of patients with atrial fibrillation not treated with oral anticoagulants. Scand J Prim Health Care 2014; 32: 226-231.
7. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review. Am J Med 2010; 123: 638-645.
8. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
9. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6: 1500-1506.
10. Stoica A, Sorodoc V, Lionte C, Jaba IM, Costache I, Anisie E, et al. Acute cardiac dyspnea in the emergency department: diagnosis value of NT-proBNP and galectin-3. J Int Med Res 2018; 17: 300060518798257 [Epub ahead of print].
11. Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran R. Prosthetic Heart Valve Thrombosis. J Am Coll Card 2016; 68(24): 2670-2689.
12. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. The 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962.
13. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Eur Heart J 2018; 19: [Epub ahead of print].
14. Xian Y, O’Brien EC, Liang L, Xu H, Schwamm LH, Fonarow GC, et al. Association of Preceding Antithrombotic Treatment with Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients with Atrial Fibrillation. JAMA 2017; 317(10): 1057-1067.
Published
2018-12-27
Section
INTERNAL MEDICINE - PEDIATRICS